Novartis Ag

Yong Jia

Scott Glaser

Jian Shi

Gerald Lelais

Michael DiDonato

Sarah Rue

Christian Cho-Hua Lee

Alexandra Kraus

Anna Galkin

Xenia Karola Wezler

Klaus Felix Hartlepp

NgocDiep Le

Christoph Erkel

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant 'gatekeeper' T790M mutation, or any combination of these mutations.

Methods for treating EGFR mutant cancers

Growing community of inventors

San Diego, CA, United States of America

Yong Jia